Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Fengxiang Huang
Haiyan Yang
Wenguang Bao
Yehong Bin
Shengsheng Zhou
Man Wang
Xiaoping Lv
机构：
[1] The First Affiliated Hospital of Guangxi Medical University,Department of Oncology
[2] The First Affiliated Hospital of Guangxi Medical University,Department of Gastroenterology
来源：
Clinical and Translational Oncology | 2024年 / 26卷
关键词：
Metastatic colorectal cancer; TAS-102; Efficacy; Safety; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：468 / 476
页数：8
相关论文
共 50 条
  • [1] Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis
    Huang, Fengxiang
    Yang, Haiyan
    Bao, Wenguang
    Bin, Yehong
    Zhou, Shengsheng
    Wang, Man
    Lv, Xiaoping
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 468 - 476
  • [2] A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
    Andersen, Stig E.
    Andersen, Ida B.
    Jensen, Benny V.
    Pfeiffer, Per
    Ota, Takayo
    Larsen, Jim S.
    [J]. ACTA ONCOLOGICA, 2019, 58 (08) : 1149 - 1157
  • [3] Neutropenia as a predictor of efficacy in the treatment of metastatic colorectal cancer with TAS-102 (trifluridine - tipiracil).
    Rodriguez Garces, Maria Yeray
    Senin, Loreto Dominguez
    Urbano, Maria Amor
    Tarazona, Victoria Avino
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15564 - E15564
  • [4] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
    Kotani, D.
    Kuboki, Y.
    Yasuda, K.
    Nakamura, Y.
    Kawazoe, A.
    Bando, H.
    Taniguchi, H.
    Shitara, K.
    Yoshino, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
  • [5] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
  • [6] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiaochen
    Qiu, Huafeng
    Chen, Yunwang
    Wang, Mingxing
    Zhu, Pengfei
    Pan, Shuangyue
    Deng, Yaya
    Yang, Liu
    Chen, Zheling
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer
    Narihiro, Satoshi
    Suwa, Katsuhito
    Ushigome, Takuro
    Ohtsu, Masamichi
    Ryu, Syunjin
    Shimoyama, Yuya
    Okamoto, Tomoyoshi
    Yanaga, Katsuhiko
    [J]. IN VIVO, 2018, 32 (06): : 1643 - 1646
  • [8] Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial
    Pfeiffer, P.
    Yilmaz, M.
    Moller, S.
    Zitnjak, D.
    Maltha, L.
    Krogh, M.
    Winther, S.
    Petersen, L.
    Hejlersen, F.
    Thomsen, K.
    Qvortrup, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [9] Integrated safety summary for trifluridine/tipiracil (TAS-102)
    Falcone, Alfredo
    Ohtsu, Atsushi
    Van Cutsem, Eric
    Mayer, Robert J.
    Buscaglia, Michele
    Bendell, Johanna C.
    Kopetz, Scott
    Bebeau, Paul
    Yoshino, Takayuki
    [J]. ANTI-CANCER DRUGS, 2018, 29 (01) : 89 - 96
  • [10] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    [J]. BMC CANCER, 2019, 19 (01)
12345